2022 Investor Conference
Forward-Looking Statements
The presentations being made on May 25, 2022 include forward-looking statements concerning Baxter's financial results, R&D pipeline, including planned
product launches (many of which are subject to regulatory approval and may require additional investment) and results of clinical trials, business development
activities (including anticipated cost and revenue synergies), capital structure, cost savings initiatives, Baxter's long range plan (which includes financial outlook
for 2022 and 2022-2025) and other growth strategies. These forward-looking statements are based on assumptions about many important factors, including the
following, which could cause actual results to differ materially from those in the forward-looking statements: the impact of global economic conditions (including
the ongoing war in Ukraine and the related economic sanctions being imposed globally in response to the conflict and potential trade wars) and public health
crises and epidemics, such as the ongoing coronavirus (COVID-19) pandemic, on the company and its employees, customers and suppliers, including foreign
governments in countries in which the company operates; demand for and market acceptance of risks for new and existing products; product development risks
(including satisfactory clinical performance and obtaining required regulatory approvals); product quality or patient safety concerns; continuity, availability and
pricing of acceptable raw materials and component supply (including impacts from COVID-19); inability to create additional production capacity in a timely
manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics,
geopolitical crises, regulatory actions or otherwise); accurate identification of and execution on business development and R&D opportunities and realization of
anticipated benefits (including the acquisitions of Cheetah Medical, Seprafilm Adhesion Barrier, specified OUS rights to Caelyx/Doxil, full U.S. and specific OUS
rights to Transderm Scop, PerClot, Hillrom and certain rights to Zosyn in the U.S. and Canada); breaches or failures of Baxter's information technology systems or
products, including by cyberattack, unauthorized access or theft; the adequacy of Baxter's cash flows from operations and other sources of liquidity to meet its
ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory
bodies and other governmental authorities, including FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies,
including the continued delay in lifting the warning letter at Baxter's Ahmedabad facility; the outcome of pending or future litigation, including the opioid litigation
and current and future ethylene oxide litigation or other claims; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney
health policy and reimbursement, which may substantially change the U.S. end-stage renal disease market and demand for the company's peritoneal dialysis
products, necessitating significant multiyear capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; future
actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of
government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive
technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the
manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation
of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and
Anti-Abuse Tax or the Build Back Better framework; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter's
most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter's website. Baxter does not undertake
to update its forward-looking statements.
Baxter | 2022 Investor Conference
73View entire presentation